M
Matinas BioPharma Holdings, Inc. (MTNB)
ASE – Real Time Price. Currency in USD
0.59
-0.05 (-7.84%)
At close: May 12, 2026, 3:59 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
ASE – Real Time Price. Currency in USD
0.59
-0.05 (-7.84%)
At close: May 12, 2026, 3:59 PM EDT
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company’s LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
| Name | Position |
|---|---|
| Mr. Jerome D. Jabbour J.D. | Co-Founder, Chairman, CEO, President & Interim CFO |
| Date | Type | Document |
|---|---|---|
| 2026-05-08 | 10-Q | form10-q.htm |
| 2026-04-03 | 8-K | form8-k.htm |
| 2026-03-31 | 10-K | form10-k.htm |
| 2026-01-23 | 8-K | form8-k.htm |
| 2025-12-12 | 8-K | form8-k.htm |
| 2025-11-21 | 8-K | form8-k.htm |
| 2025-11-10 | 10-Q | form10-q.htm |
| 2025-08-18 | 8-K | form8-k.htm |
| 2025-08-14 | 10-Q | form10-q.htm |
| 2025-08-06 | 8-K | form8-k.htm |